As stated by Zacks, analysts forecast how Aurinia Pharmaceuticals Inc, for the present quarter, will post incomes of $0.15 per each share. 3 experts have presented their estimations of how much they expect Aurinia Pharmaceuticals Inc will post as their proceeds. Their approximations range between $0.11 and $0.18. In the same quarter of the previous year, Aurinia Pharmaceuticals Inc stated how their proceeds were $0.19 per every share. This shows a positive development rate of 21.1% relative to the previous year. The upcoming quarterly proceeds report of Aurinia Pharmaceuticals is expected on the 8th of August.
Experts predict how, for the present year, the Aurinia Pharmaceuticals Inc on average, will state the full-year proceeds to be $0.66 per each share. EPS approximations range between $0.77 and $0.45. Analysts forecast how, for the upcoming year, the company will report proceeds of $0.32 per each share. EPS approximations range between $0.53 and $0.06.
The most recently quarterly proceeds report was presented by Aurinia Pharmaceuticals on the 19th of March. The firm missed experts’ consensus approximates by $0.03, when they stated $0.17 EPS for the quarter. Relative to expert approximate of $0.05M, Aurinia Pharmaceuticals generated $0.03M in revenue during the quarter. The firm reported a negative return on equity of 48.36%, as well as a negative net margin of 8,435.08%.
According to a research article published on the 25th of January, Zacks Investment Research decreased their shares, from ‘buy’ to ‘hold’ rating, of Aurinia Pharmaceuticals. A research article published on the 10th on April stated how BidaskClub decreased their shares, from ‘hold’ to ‘sell’ rating, of Aurinia Pharmaceuticals Inc. According to a research article published on the 20th of March, Raymond James raised their price objectives from $9 to $11 on AuriniaPharmaceuticals’ shares, they also gave the firm a rating of ‘outperform’. According to another research article published on the 20th of March, the Royal Bank of Canada also raised its price objective on Aurinia Pharmaceuticals’ shares by the same amount as Raymond James.